Your basket is currently empty!
Cabo + nivo & ipi delays kidney cancer progression
Adding cabozantinib (Cabometyx) to nivolumab (Opdivo) and ipilimumab (Yervoy) improved progression-free survival ...
News Archive
Cabozantinib
Cabo+Tecentriq combo shows promise in advanced ccRCC
Treatment with Cabometyx (cabozantinib) in combination with Tecentriq (atezolizumab) demonstrated promising ...
Cabo/atezo phase 3 combo RCC trial launched
The phase 3 CONTACT-03 trial is exploring the combination of the multikinase inhibitor and immunotherapy agent in ...
cabozantinib, new first line treatment for kidney cancer
Once-daily tablet, CABOMETYX®▼(cabozantinib), approved by NICE as a first-line treatment for adult patients with ...
Cabozantinib Effective in Real-World Analysis for Relapsed Mrcc
Cabozantinib is a safe and effective treatment option for patients with relapsed renal cell carcinoma (RCC) in ...
CABOSUN trail shines for Cabozantinib
New CABOSUN Data Show Better PFS With Cabozantinib in mRCC
Read the full article HERE
Updated results from the ...
Cabozantinib Yields Similar QoL Outcomes to Everolimus in RCC
Patients with advanced renal cell carcinoma had an improved time to deterioration (TTD) and similar quality of ...
Cabozantinib Bests Everolimus in RCC with Bone Metastases
Cabozantinib (Cabometyx) was more effective than everolimus (Afinitor) in patients with advanced renal cell ...
New treatment option: Cabozantinib is now available for use in the NHS for advanced kidney cancer patients
Kidney Cancer UK is delighted that National Institute for Health and Care Excellence (NICE) has recommended the ...
Recent developments and future clinical trials for advanced kidney cancer:
immunotherapy and drug combinations including cabozantinib and nivolumab.
*You may find our Glossary of Terms ...
SMC approve of nivolumab and cabozantinib
Statement from Kidney Cancer Scotland on the news of the SMC’s approval of nivolumab and cabozantinib for late ...
Hopes for Cabozantinib NICE recommendation
Kidney Cancer UK is very disappointed to hear that at the midpoint of the Single Technology Appraisal (STA) of ...
